Spina Bifida In-Utero Market is segmented By Diagnosis (Ultrasound, MRI, Amniocentesis), By Treatmen...
Market Size in USD Bn
CAGR8.4%
Study Period | 2025-2032 |
Base Year of Estimation | 2024 |
CAGR | 8.4% |
Market Concentration | High |
Major Players | Johnson & Johnson Inc, Pfizer Inc, Medtronic, Boston Scientific Corporation, Abbott Laboratories and Among Others |
The Spina Bifida In-Utero - Market is estimated to be valued at USD 2.94 billion in 2025 and is expected to reach USD 5.17 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.4% from 2025 to 2032. The increasing investments from large medical device companies as well as the efforts of non-profit organizations to spread awareness about spina bifida are fueling the growth of this market.
The market is expected to witness positive growth over the forecast period. Rising incidence rates of spina bifida and other neural tube defects worldwide will drive the need for screening, diagnostic and treatment procedures. Furthermore, development of advanced prenatal screening and diagnostic techniques with higher accuracy is also expected to support the market growth. However, social stigma and religious restrictions associated with abortion in some regions may hinder the market expansion to some extent.